Evidence map›Paper›PMID 39055237›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2024

Identification of risk groups for advanced liver fibrosis in the general population using the Fibrosis-3 index.

Kazuya Kariyama, Miwa Kawanaka, Kazuhiro Nouso, Akiko Wakuta, Shohei Shiota, Akemi Kurisu, Aya Sugiyama, Tomoyuki Akita, Takashi Kumada, Junko Tanaka and 1 more

Abstract read
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kazuya KariyamaDepartment of Gastroenterology and Liver Disease Center Okayama City Hospital Okayama City Okayama Japan.ORCID https://orcid.org/0000-0003-3996-7502
Miwa KawanakaDepartment of General Internal Medicine 2 General Medical Center, Kawasaki Medical School Okayama City Okayama Japan.ORCID https://orcid.org/0000-0003-2341-5199
Kazuhiro NousoDepartment of Gastroenterology and Liver Disease Center Okayama City Hospital Okayama City Okayama Japan.ORCID https://orcid.org/0000-0002-2018-0008
Akiko WakutaDepartment of Gastroenterology and Liver Disease Center Okayama City Hospital Okayama City Okayama Japan.ORCID https://orcid.org/0009-0005-6178-6769
Shohei ShiotaDepartment of Gastroenterology and Liver Disease Center Okayama City Hospital Okayama City Okayama Japan.ORCID https://orcid.org/0009-0005-3104-385X
Akemi KurisuDepartment of Epidemiology Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima Japan.ORCID https://orcid.org/0000-0003-1021-5243
Aya SugiyamaDepartment of Epidemiology Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima Japan.ORCID https://orcid.org/0000-0002-8087-4319
Tomoyuki AkitaDepartment of Epidemiology Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima Japan.ORCID https://orcid.org/0000-0002-1056-3611
Takashi KumadaDepartment of Gastroenterology and Hepatology Ogaki Municipal Hospital Ogaki City Gifu Japan.ORCID https://orcid.org/0000-0001-5871-3802
Junko TanakaDepartment of Epidemiology Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima Japan.ORCID https://orcid.org/0000-0002-5669-4051
Real‐Life Practice Experts for HCC (RELPEC) Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aim: We conducted a study using the Fibrosis-3 (FIB-3) index, which is the established age-independent index of fibrosis in nonviral liver disease and addresses the limitations of the FIB-4 index in older age group, to assess the liver fibrosis risk among diverse demographic groups in the general population. Methods: We analyzed 31 327 individuals who underwent health examinations between 2013 and 2020 and investigated the distribution of the FIB-3 index by age group. In addition, we examined the age distribution of the FIB-3 index stratified by background factors, such as sex, body mass index (BMI), alcohol consumption habits, and the presence or absence of fatty liver. Results: In terms of age-specific distribution, the FIB-3 index remained below 1.5 in >90% of cases until the age of 50 years but exceeded 1.5 beyond the age of 50 years, in approximately 30% among those aged 70 years. Notably, the FIB-3 index above 31 years old was significantly higher in men than in women. Among the different BMI categories, individuals with BMI < 18.5 exhibited the highest prevalence of fibrosis. Habitual drinkers had a higher proportion with FIB-3. index ≥1.5, and some had FIB-3 index ≥2.5, raising the suspicion of advanced hepatic fibrosis. No distinct association was identified between the FIB-3 index and the presence of fatty liver. Conclusions: The FIB-3 index was useful for identifying cases of advancing hepatic fibrosis in a health checkup population. Liver fibrosis progresses with age in the general population, especially among men, those with low BMI, and habitual drinkers.

Indexed as

FIB‐3 indexFIB‐4 indexgeneral health checkupliver fibrosismetabolic dysfunction‐associated liver disease

Identifiers

PMID39055237
PMCPMC11271256

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.